Myonexus Therapeutics, Inc., a New Albany, Ohio-based clinical-stage biotechnology company developing transformative gene therapies for limb-girdle muscular dystrophies (LGMDs), completed a $2.5m seed financing.
CincyTech, Rev1 Ventures, The Jain Foundation, and GFB ONLUS joined initial investors from the LGMD community.
Founded in 2017 and led by Michael Triplett, PhD, President and Chief Executive Officer, and Bruce Halpryn, PhD, Chief Operating Officer, Myonexus is a clinical stage, rare disease gene therapy company developing treatments for Limb-girdle muscular dystrophies (LGMDs) based on research at Nationwide Children’s Hospital, a leader in neuromuscular gene therapy discovery and translational research.
The company intends to use the funds to initiate a systemic Phase 1/2a clinical trial of MYO-101, its gene therapy candidate for treating LGMD2E (beta-sarcoglycanopathy), in early 2018. Myonexus’ pipeline also includes:
– MYO-102, a gene therapy candidate for LGMD2D (alpha-sarcoglycanopathy) currently completing a Phase 1/2a clinical trial,
– MYO-201, a gene therapy candidate for LGMD2B (dysferlinopathy) currently in Phase 1, MYO-103, a preclinical gene therapy candidate for LGMD2C (gamma-sarcoglycanopathy), and
– MYO-301, a preclinical gene therapy candidate for LGMD2L (anoctamin 5).